HLB Life Science Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

10.02

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

11.36%

Rev. gr., 5y

-0.89%

Revenues

97.99b

-1.61%

Net income

-5.98b

L-88.98%

CFO

-10.02b

L-66.33%

Earnings

Feb 11, 2025

Profile

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/Ã-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.

URL

http://www.hlb-ls.com/

IPO date

Nov 25, 2008

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	97,990,441 -1.61%	99,591,376 86.17%	53,494,248 -41.73%
Cost of revenue	109,726,265	112,298,914	66,207,566
Unusual Expense (Income)
NOPBT	(11,735,824)	(12,707,539)	(12,713,318)
NOPBT Margin
Operating Taxes	(590,063)	(6,479,000)	(4,332,854)
Tax Rate
NOPAT	(11,145,761)	(6,228,539)	(8,380,464)
Net income	(5,983,400) -88.98%	(54,277,435) 10.43%	(49,151,656) -11.91%
Dividends
Dividend yield
Proceeds from repurchase of equity	(679,971)	459,369	(46,849)
BB yield	0.05%	-0.04%	0.00%
Debt
Debt current	114,743,482	10,452,100	668,003
Long-term debt	53,180,367	137,021,270	3,952,623
Deferred revenue	8	832,407	452,623
Other long-term liabilities	1,651,784	1,884,492	941,376
Net debt	(56,973,768)	(51,298,960)	(164,222,923)
Cash flow
Cash from operating activities	(10,015,987)	(29,743,908)	(14,084,072)
CAPEX	(20,618,342)	(11,653,558)	(2,610,102)
Cash from investing activities	(8,882,725)	(72,643,336)	8,821,727
Cash from financing activities	4,785,941	102,096,453	(641,085)
FCF	(34,956,620)	(85,245,005)	(5,712,472)
Balance
Cash	78,859,684	131,440,944	139,960,554
Long term investments	146,037,933	67,331,386	28,882,994
Excess cash	219,998,094	193,792,761	166,168,836
Stockholders' equity	89,198,811	41,222,654	5,717,254
Invested Capital	310,243,408	344,069,725	246,456,618
ROIC
ROCE
EV
Common stock shares outstanding	109,199	100,970	99,344
Price	11,450.00 8.02%	10,600.00 -14.86%	12,450.00
Market cap	1,250,333,622 16.82%	1,070,284,682 -13.47%	1,236,836,759
EV	1,219,222,502	1,020,327,420	1,073,036,705
EBITDA	(4,039,834)	(7,736,930)	(10,644,622)
EV/EBITDA
Interest	21,650,382	9,870,396	1,256,054
Interest/NOPBT